Detailed imaging and genetic analysis reveal a secondary BRAFL505H resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

Publisher： John Wiley & Sons Inc

E-ISSN： 1755-148x|28|3|318-323

ISSN： 1755-1471

Source： PIGMENT CELL & MELANOMA RESEARCH, Vol.28, Iss.3, 2015-05, pp. : 318-323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 3, 2015-05 ,pp. : 254-266

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phosphoproteomic analysis of basal and therapy‐induced adaptive signaling networks in BRAF and NRAS mutant melanoma

By  

PROTEOMICS, Vol. 15, Iss. 2-3, 2015-01 ,pp. : 327-339

John Wiley & Sons Inc

Access to resources Recommend Favorite

Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 31, Iss. 2, 2018-03 ,pp. : 341-344

John Wiley & Sons Inc

Access to resources Recommend Favorite

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

By Chan Xian Yang   Singh Alamdeep   Osman Narin   Piva Terrence J.  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. : 1527-1527

MDPI

Access to resources Recommend Favorite

Genetic analysis of the ‘uveal melanoma’ C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 3, 2015-05 ,pp. : 357-359

John Wiley & Sons Inc

Access to resources Recommend Favorite